+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07276425

Evaluating Early and Long-Term Effects of Dupilumab Treatment on Immune Changes and Symptoms in Adults with Prurigo Nodularis

Led by UMC Utrecht · Updated on 2025-12-18

40

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of dupilumab, a targeted therapy for people with moderate-to-severe prurigo nodularis PN, a skin condition causing itchy nodules. This research aims to gather real-world data and understand how dupilumab works on PN to help improve personalized treatment approaches. The study is observational and led by UMC Utrecht. Participants will receive dupilumab as part of their standard care, starting with a 600 mg loading dose followed by 300 mg injections every two weeks. The study will track treatment effects and immune changes over a year, up to 52 weeks of treatment. There are no comparator groups since this is an observational study. Throughout the study, researchers will monitor itch severity using the Peak Pruritus Numerical Rating Scale and the Investigator Global Assessment of PN stage. They will also measure drug survival, adverse events, and immune system markers in the skin and blood. This includes T cell subtypes, protein levels, and epigenetic changes. The total participation lasts up to 52 weeks, during which safety and treatment responses are closely observed.

CONDITIONS

Brief Title

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

Research Team

M

Marjolein de Bruin-Weller, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here